Leading interventional cardiologist suggests robotic system from Corindus can potentially raise the standard of care for percutaneous coronary intervention (PCI); podium presentation made at ‘CRT 2010’

Clinical trials imminent for CorPath™ System

NATICK, Mass., March 1, 2010—Corindus Vascular Robotics—an emerging medical technology company focused on precision vascular robotic systems designed to improve patient outcomes while protecting physicians from well-documented occupational hazards—announced today that the Company’s CorPath vascular robotic system was the subject of a podium presentation last week at ‘CRT 2010’ by George W. Vetrovec, M.D., of Virginia Commonwealth University Medical Center, in which he concluded that CorPath “can potentially raise the standard of care in PCI by improving standardization, reproducibility and accuracy” of the procedure.

“The CorPath vascular robotic system can potentially foster a new standard of care for precise stent deployment—which is a big challenge today due to the limited precision associated with manually controlled PCI procedures,” said Dr. Vetrovec, Director of the Adult Cardiac Catheterization Laboratory, Associate Chairman of Medicine for Clinical Affairs in the Department of Internal Medicine, and a member of the VCU Health System Board of Directors. “My personal experience using the CorPath system leads me to believe that the system potentially offers interventional cardiologists and their patients several significant procedural advantages over the current manual PCI procedure.”

“In addition to the potential for enhancing PCI outcomes for patients, physicians may have additional compelling reasons for wanting to use CorPath. Indeed, there are many published studies which show that the cath lab is a hazardous work environment, where physicians are being exposed to increased risk of not only cancer but also spinal and other problems,” said David M. Handler, President and CEO of Corindus.

“Our CorPath system is designed to significantly reduce radiation exposure, physician fatigue and other occupational hazards to physicians by allowing him or her to operate in an ergonomically correct position while being shielded from harmful and repeated radiation exposure. Our product offering comes at a time when the FDA has, just last month, unveiled its initiative to reduce unnecessary radiation exposure from medical imaging. Certainly CorPath is designed to conform perfectly with the spirit of the FDA’s initiative,” added Handler. “We are looking forward to the initiation of CorPath clinical trials.”

(more)
Percutaneous coronary intervention (PCI), commonly known as ‘coronary angioplasty’ or simply ‘angioplasty’, is a procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is performed by an interventional cardiologist in a cath lab utilizing x-ray angiography imaging—which exposes physicians to significant occupational hazards, including radiation exposure as well as chronic orthopedic ailments and fatigue due to the required use of heavy lead protection garments.

About Corindus Vascular Robotics

Corindus designs, manufactures and commercializes precision vascular robotic systems for use in minimally invasive procedures. The Company’s disposable medical device business model is enabled by a simple and low-cost console. The Company’s initial product, the CorPath™ system, is the world’s first to precisely drive coronary guidewires and stent/balloon catheters during percutaneous coronary intervention (PCI) procedures performed in a cath lab. While Corindus is focused initially on PCIs, its open-platform technology and IP allow the Company to address other segments of the vascular market—including peripheral and other complex cardiac interventions such as structural heart disease repair.

NOTE: The Corindus CorPath™ system is an investigational device and limited by federal law to investigational use only.

#####